Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Hospital Medical Center, Cincinnati
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Sun Yat-sen University
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
Baylor College of Medicine
St. Jude Children's Research Hospital
Children's Hospital Medical Center, Cincinnati
Valent Technologies, LLC
Sun Yat-sen University
University of Pittsburgh
Federation Francophone de Cancerologie Digestive
Memorial Sloan Kettering Cancer Center
Instituto do Cancer do Estado de São Paulo
Shanghai Children's Medical Center
Eureka Therapeutics Inc.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Nemours Children's Clinic
Universitätsklinikum Hamburg-Eppendorf
Bayer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Masonic Cancer Center, University of Minnesota
University Hospital, Strasbourg, France
New York Medical College
Leiden University Medical Center
RenJi Hospital
West China Hospital
TRPHARM
Shanghai Children's Medical Center
Emory University